ATX-MS-1467 is a potential disease-modifying therapy for relapsing-remitting multiple sclerosis (RRMS). Its developer, Apitope, reports that peptide-based therapeutic agent could benefit up to 70 percent of people with MS who have a specific genetic profile.

ATX-MS-1467 consists of four short peptides derived from the basic protein of myelin, which is a key auto-antigen (a trigger for an auto-immune response), in MS. ATX-MS-1467 aims to induce an immunological tolerance in T-cells to key auto-antigens involved in the clinical development of MS. In other words, it seeks to reduce MS attacks by desensitizing (switching off) the autoimmune response to myelin. Gradually increased doses of ATX-MS-1467 could make the immune system adjust to their presence and prevent immune attacks against myelin.

Studies Involving ATX-MS-1467

Following encouraging preliminary results from a small-scale Phase 1 clinical trial in six patients with secondary progressive multiple sclerosis (SPMS), a second Phase 1 study was successfully completed (NCT01097668). The second study assessed the safety and biological parameters of ATX-MS-1467 in 43 RRMS patients. The primary endpoint was safety and tolerability, determined through adverse effects and MRI scans. A secondary goal was identifying early signs of effectiveness. MRI scans showed a significant decrease in new lesions, which is an early indicator of potential effectiveness.

An open-label Phase 2a study (NCT01973491) evaluated the effects of ATX-MS-1467 in 19 people with relapsing MS. ATX-MS-1467 was administered under the skin every two weeks for 20 weeks. Following an initial dosing of 50 to 200 mcg in the initial four weeks of treatment, a dose of 800 mcg was administered every two weeks for another 16 weeks.

Trial results, released in February 2017, reported statistically significant reductions in the number of brain lesions measured by MRI during treatment, as well as a significant reduction in lesion volume. The data also showed a strong tendency toward improvement in the Multiple Sclerosis Functional Composite (MSFC) score, a clinically used indicator of changes in disability. There were no treatment-related serious adverse events and the drug’s side effects profile was mild.

Apitope is now preparing for a Phase 2b trial, with a placebo or non-treatment group, to assess the clinical efficacy of ATX-MS-1467.

Note: Multiple Sclerosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.